Course of Visual Decline in Relation to the Best1 Genotype in Vitelliform Macular Dystrophy

详细信息    查看全文

• 作者：Judith C. Booij ; Camiel J.F. Boon ; Mary J. van Schooneveld ; Jacoline B. ten Brink ; Arne Bakker ; Paulus T.V.M. de Jong ; Carel B. Hoyng ; Arthur A.B. Bergen ; Caroline C.W. Klaver
• 刊名：Ophthalmology
• 出版年：2010
• 出版时间：July 2010
• 年：2010
• 卷：117
• 期：7
• 页码：1415-1422
• 全文大小：842 K

文摘

Purpose

To describe the disease course in patients with vitelliform macular dystrophy (VMD) with a Best1 mutation and to determine the association between Best1 genotype and visual prognosis.

Design

Consecutive case series.

Participants

Fifty-three patients with VMD with Best1 mutations from 27 Dutch families, aged 11 to 87 years.

Methods

Best-corrected visual acuity (VA), fundus appearance, and Arden ratio on the electro-oculogram (EOG) during clinical follow-up were assessed from medical records. Mutation analysis of the Best1 gene was performed on DNA samples using denaturing high-pressure liquid chromatography and direct sequencing.

Main Outcome Measures

Cumulative lifetime risk of visual decline below 0.5, 0.3, and 0.1 for the entire group and stratified for genotype.

Results

Median age of onset of visual symptoms was 33 years (range: 2–78). The cumulative risk of VA below 0.5 (20/40) was 50 % at 55 years and 75 % at 66 years. The cumulative risk of decline less than 0.3 (20/63) was 50 % by age 66 years and 75 % by age 74 years. Two patients progressed to VA less than 0.1 (20/200). Fourteen different mutations were found. Most patients (96 % ) had missense mutations; the Thr6Pro, Ala10Val, and Tyr227Asn mutations were most common. Visual decline was significantly faster in patients with an Ala10Val mutation than either the Thr6Pro or the Tyr227Asn mutation (P=0.001).

Conclusions

Age of onset of visual symptoms varies greatly among patients with VMD. All patients show a gradual decrease in VA, and most progress to visual impairment at a relatively late age. Our data suggest a phenotype–genotype correlation, because the Ala10Val mutation has a more rapid disease progression than other common mutations.

Financial Disclosure(s)

The author(s) have no proprietary or commercial interest in any materials discussed in this article.